Pathophysiology and clinical management of cardiac sarcoidosis

Nature Reviews Cardiology

Volumn 12, Issue 5, 2015, Pages 278-288

  Hamzeh, Nabeel ^a   Steckman, David A ^b   Sauer, William H ^c   Judson, Marc A ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; MINERALOCORTICOID ANTAGONIST; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

CARDIOVASCULAR MAGNETIC RESONANCE; CONGESTIVE HEART FAILURE; ECG ABNORMALITY; ECHOCARDIOGRAPHY; FAINTNESS; HEART FAILURE; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HISTOPATHOLOGY; HOLTER MONITORING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MEDICAL HISTORY; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS; SCREENING; SUDDEN CARDIAC DEATH; BIOPSY; CARDIOMYOPATHIES; CATHETER ABLATION; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; ELECTROCARDIOGRAPHY;

ANTI-ARRHYTHMIA AGENTS; BIOPSY; CARDIOMYOPATHIES; CATHETER ABLATION; DEFIBRILLATORS, IMPLANTABLE; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; ELECTROCARDIOGRAPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SARCOIDOSIS;

EID: 84928589143     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.22     Document Type: Review

References (97)

1. Hunninghake, G. W. et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/ World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc. Diffuse Lung. Dis. 16, 149-173 (1999).
2. Statement on Sarcoidosis. Am. J. Respir. Crit. Care Med. 160, 736-755 (1999).
3. Gerke, A. K. & Hunninghake, G. The immunology of sarcoidosis. Clin. Chest Med. 29, 379-390 (2008).
4. Iwai, K., Takemura, T., Kitaichi, M., Kawabata, Y. & Matsui, Y. Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern. Acta Pathol. Jpn. 43, 377-385 (1993).
5. Perry, A. & Vuitch, F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch. Pathol. Lab. Med. 119, 167-172 (1995).
6. Silverman, K. J., Hutchins, G. M. & Bulkley, B. H. Cardiac sarcoid: a clinicopathological study of 84 unselected patients with systemic sarcoidosis. Circulation 58, 1204-1211 (1978).
7. Iwai, K. et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 11, 26-31 (1994).
8. Huang, C. T., Heurich, A. E., Sutton, A. L. & Lyons, H. A. Mortality in sarcoidosis. A changing pattern of the causes of death. Eur. J. Respir. Dis. 62, 231-238 (1981).
9. Tavora, F. et al. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am. J. Cardiol. 104, 571-577 (2009).
10. Kim, J. S. et al. Cardiac sarcoidosis. Am. Heart. J. 157, 9-21 (2009).
11. Mehta, D. et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 133, 1426-1435 (2008).
12. Judson, M. A., Boan, A. D. & Lackland, D. T. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc. Diffuse Lung. Dis. 29, 119-127 (2012).
13. Baughman, R. P. et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am. J. Respir. Crit. Care. Med. 164, 1885-1889 (2001).
14. Judson, M. A., Baughman, R. P., Teirstein, A. S., Terrin, M. L. & Yeager, H. Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc. Diffuse Lung. Dis. 16, 75-86 (1999).
15. Rossman, M. D. et al. HLA and environmental interactions in sarcoidosis. Sarcoidosis Vasc. Diffuse Lung. Dis. 25, 125-132 (2008).
16. Kuroda, H. et al. Relationship between cytokine single nucleotide polymorphisms and sarcoidosis among Japanese subjects. Sarcoidosis Vasc. Diffuse Lung. Dis. 30, 36-42 (2013).
17. Naruse, T. K. et al. HLA-DQB1∗0601 is primarily associated with the susceptibility to cardiac sarcoidosis. Tissue Antigens 56, 52-57 (2000).
18. Takashige, N. et al. Genetic polymorphisms at the tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens 54, 191-193 (1999).
19. Kandolin, R. et al. Cardiac sarcoidosis: epidemiology, characteristics and outcome over 25 years in a nationwide study. Circulation http://dx.doi.org/10.1161/CIRCULATIONAHA.114.011522.
20. Abeler, V. Sarcoidosis of the cardiac conducting system. Am. Heart J. 97, 701-707 (1979).
21. Winters, S. L. et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J. Am. Coll. Cardiol. 18, 937-943 (1991).
22. Koplan, B. A., Soejima, K., Baughman, K., Epstein, L. M. & Stevenson, W. G. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm 3, 924-929 (2006).
23. Banba, K. et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm 4, 1292-1299 (2007).
24. Jefic, D. et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 6, 189-195 (2009).
25. Furushima, H. et al. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin. Cardiol. 27, 217-222 (2004).
26. Uusimaa, P. et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace 10, 760-766 (2008).
27. Naruse, Y. et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ. Arrhythm. Electrophysiol. 7, 407-413 (2014).
28. Crawford, T. et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ. Arrhythm. Electrophysiol. 7, 1109-1115 (2014).
29. Shafee, M. A. et al. Delayed enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis. J. Cardiol. 60, 448-453 (2012).
30. Tokuda, M. et al. Catheter ablation of ventricular tachycardia in nonischemic heart disease. Circ. Arrhythm. Electrophysiol. 5, 992-1000 (2012).
31. Willner, J. M., Viles-Gonzalez, J. F., Coffey, J. O., Morgenthau, A. S. & Mehta, D. Catheter ablation of atrial arrhythmias in cardiac sarcoidosis. J. Cardiovasc. Electrophysiol. 25, 958-963 (2014).
32. Viles-Gonzalez, J. F. et al. Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. Chest 143, 1085-1090 (2013).
33. Cain, M. et al. Are atrial arrhythmias under-recognized in patients with cardiac sarcoidosis? [abstract] J. Am. Coll. Cardiol. 59, E727 (2012).
34. Cain, M. A. et al. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am. J. Cardiol. 113, 1556-1560 (2014).
35. Sekhri, V., Sanal, S., Delorenzo, L. J., Aronow, W. S. & Maguire, G. P. Cardiac sarcoidosis: a comprehensive review. Arch. Med. Sci. 7, 546-554 (2011).
36. Zipse, M. et al. Atrial arrhythmias are common and arise from diverse mechanisms in patients with cardiac sarcoidosis. Heart Rhythm 2013, 1-2 (2013).
37. January, C. T. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 64, e1-e76 (2014).
38. Biviano, A. B. et al. Focal left atrial tachycardias not associated with prior catheter ablation for atrial fibrillation: clinical and electrophysiological characteristics. Pacing Clin. Electrophysiol. 35, 17-27 (2012).
39. Nery, P. B. et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J. Cardiovasc. Electrophysiol. 25, 875-881 (2014).
40. Yoshida, Y. et al. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am. Heart J. 134, 382-386 (1997).
41. Kandolin, R., Lehtonen, J. & Kupari, M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ. Arrhythm. Electrophysiol. 4, 303-309 (2011).
42. Chapelon-Abric, C. et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 83, 315-334 (2004).
43. Suzuki, T., Kanda, T., Kubota, S., Imai, S. & Murata, K. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest 106, 1021-1024 (1994).
44. Schuller, J. L. et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J. Cardiovasc. Electrophysiol. 22, 1243-1248 (2011).
45. Mohamed, H., Lamaan, A., Bilal, S., Jo, M. & Mithilesh, K. D. Fragmented QRS complexes on 12-lead ECG: a marker of cardiac sarcoidosis as detected by gadolinium cardiac magnetic resonance imaging. Ann. Noninvasive Electrocardiol. 14, 319-326 (2009).
46. Gialafos, E. et al. P wave analysis in patients with sarcoidosis. Int. J. Clin. Med. 04, 388-394 (2013).
47. Matsumoto, S. et al. Noninvasive diagnosis of cardiac sarcoidosis using microvolt T-wave alternans. Int. Heart J. 50, 731-739 (2009).
48. Nunes, H. et al. Cardiac sarcoidosis. Semin. Respir. Crit. Care Med. 31, 428-441 (2010).
49. Kul, S. et al. Diagnostic value of strain echocardiography, galectin-3, and tenascin-C levels for the identification of patients with pulmonary and cardiac sarcoidosis. Lung 192, 533-542 (2014).
50. Yasutake, H. et al. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int. J. Cardiol. 102, 259-268 (2005).
51. Date, T. et al. Elevated plasma brain natriuretic peptide level in cardiac sarcoidosis patients with preserved ejection fraction. Cardiology 107, 277-280 (2007).
52. Baba, Y. et al. Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis. Int. Heart J. 53, 287-292 (2012).
53. Birnie, D. H. et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11, 1305-1323 (2014).
54. Smedema, J. P. et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J. Am. Coll. Cardiol. 45, 1683-1690 (2005).
55. Yoshida, A. et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur. J. Heart Fail. 15, 166-175 (2013).
56. Ordovas, K. G. & Higgins, C. B. Delayed contrast enhancement on MR images of myocardium: past, present, future. Radiology 261, 358-374 (2011).
57. Ichinose, A. et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am. J. Roentgenol. 191, 862-869 (2008).
58. Crouser, E. D., Ono, C., Tran, T., He, X. & Raman, S. V. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am. J. Respir. Crit. Care Med. 189, 109-112 (2014).
59. Vignaux, O. et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J. Comput. Assist. Tomogr. 26, 762-767 (2002).
60. Matoh, F. et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J. Cardiol. 51, 179-188 (2008).
61. Watanabe, E. et al. Late gadolinium enhancement in cardiac sarcoidosis: characteristic magnetic resonance findings and relationship with left ventricular function. J. Thorac. Imaging 28, 60-66 (2013).
62. Greulich, S. et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc. Imaging 6, 501-511 (2013).
63. Ise, T. et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 100, 1165-1172 (2014).
64. Langah, R., Spicer, K., Gebregziabher, M. & Gordon, L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J. Nucl. Cardiol. 16, 801-810 (2009).
65. Youssef, G. et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J. Nucl. Med. 53, 241-248 (2012).
66. Tahara, N. et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc. Imaging 3, 1219-1228 (2010).
67. Inglese, E. et al. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT. J. Nucl. Med. 48, 1662-1669 (2007).
68. Gormsen, L. C., Christensen, N. L., Bendstrup, E., Tolbod, L. P. & Nielsen, S. S. Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis. J. Nucl. Cardiol. 20, 1108-1115 (2013).
69. de Groot, M., Meeuwis, A. P., Kok, P. J., Corstens, F. H. & Oyen, W. J. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur. J. Nucl. Med. Mol. Imaging 32, 98-101 (2005).
70. Hamzeh, N. Y., Wamboldt, F. S. & Weinberger, H. D. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 141, 154-162 (2012).
71. From, A. M., Maleszewski, J. J. & Rihal, C. S. Current status of endomyocardial biopsy. Mayo Clin. Proc. 86, 1095-1102 (2011).
72. Diagnostic standard and guidelines for sarcoidosis [Japanese]. Jpn. J. Sarcoidosis Granulomatous Disord. 27, 89-102 (2007).
73. Judson, M. A. et al. The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. Sarcoidosis Vasc. Diffuse Lung Dis. 31, 19-27 (2014).
74. Ayyala, U. S., Nair, A. P. & Padilla, M. L. Cardiac sarcoidosis. Clin. Chest Med. 29, 493-508 (2008).
75. Kato, Y. et al. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc. Diffuse Lung Dis. 20, 133-137 (2003).
76. Yazaki, Y. et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am. J. Cardiol. 88, 1006-1010 (2001).
77. Yodogawa, K. et al. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann. Noninvasive Electrocardiol. 16, 140-147 (2011).
78. Yodogawa, K. et al. Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. J. Cardiol. 62, 320-325 (2013).
79. Chiu, C. Z. et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am. J. Cardiol. 95, 143-146 (2005).
80. Nagai, S. et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern. Med. 53, 427-433 (2014).
81. Barnabe, C., McMeekin, J., Howarth, A. & Martin, L. Successful treatment of cardiac sarcoidosis with infliximab. J. Rheumatol. 35, 1686-1687 (2008).
82. Uthman, I., Touma, Z. & Khoury, M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin. Rheumatol. 26, 2001-2003 (2007).
83. Chung, E. S. et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133-3140 (2003).
84. Aizer, A. et al. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am. J. Cardiol. 96, 276-282 (2005).
85. Mehta, D. et al. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ. Arrhythm. Electrophysiol. 4, 43-48 (2011).
86. Epstein, A. E. et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 61, e6-e75 (2013).
87. Schuller, J. L. et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J. Cardiovasc. Electrophysiol. 23, 925-929 (2012).
88. Mohsen, A. et al. Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J. Cardiovasc. Electrophysiol. http://dx.doi.org/10.1111/jce.12302.
89. Kron, J. et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 15, 347-354 (2013).
90. Bardy, G. H. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225-237 (2005).
91. Echt, D. S. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 324, 781-788 (1991).
92. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128, e240-e327 (2013).
93. Akashi, H. et al. Outcome of patients with cardiac sarcoidosis undergoing cardiac transplantation-single-center retrospective analysis. J. Cardiol. 60, 407-410 (2012).
94. Strecker, T., Zimmermann, I. & Wiest, G. H. Pulmonary and cardiac recurrence of sarcoidosis in a heart transplant recipient [German]. Dtsch. Med. Wochenschr. 132, 1159-1162 (2007).
95. Yager, J. E. et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J. Heart Lung Transplant. 24, 1988-1990 (2005).
96. Dechering, D. G. et al. Electrophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 10, 158-164 (2013).
97. Betensky, B. P. et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 9, 884-891 (2012).